TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8652323

Group type: EXPERIMENTAL
Intervention: Granisetron 1.0 mg
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Granisetron 3.0 mg
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 1799355

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6365881

Group type: EXPERIMENTAL
Intervention: Netilmicin-ticarcillin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tobramycin-ticarcillin
Number of subjects: 80
Study: 31322974

Group type: EXPERIMENTAL
Intervention: 1-mA tRNS
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2-mA tRNS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 72
Study: 30058901

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27257981

Group type: EXPERIMENTAL
Intervention: Single dose intraarticular injection of 4 ml lightly cross‐linking sodium hyaluronate (Monovisc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three consecutive intraarticular injections of 2.5 ml standard linear sodium hyaluronate (Adant) with one week intervals
Number of subjects: 40
Study: 24366001

Group type: EXPERIMENTAL
Intervention: Levobupivacaine and dexmedetomidine (Group LD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Levobupivacaine (Group L)
Number of subjects: 48
Study: 23469594

Group type: EXPERIMENTAL
Intervention: Qingchang Huashi Recipe (QHR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablet (MECT)
Number of subjects: 60
Study: 20536953

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 0
Study: 18034666

Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day, followed by 50 mg diclofenac 1 h after the last dose of voriconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control phase with a single 50-mg oral dose of diclofenac
Number of subjects: 10
Study: 16128370

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 111
Study: 12375317

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 40
Study: 10550087

Group type: EXPERIMENTAL
Intervention: FlexSure test
Number of subjects: 394

Group type: COMPARATOR
Intervention: Enzyme linked immunosorbent assay (ELISA; HM‐CAP)
Number of subjects: 394

Group type: COMPARATOR
Intervention: H pylori test and refer group
Number of subjects: 394

Group type: COMPARATOR
Intervention: Direct endoscopy referral group
Number of subjects: 394
Study: 7607138

Group type: EXPERIMENTAL
Intervention: 650 ppb nitrous acid
Number of subjects: 11

Group type: COMPARATOR
Intervention: Filtered room air (control)
Number of subjects: 11
Study: 1980733

Group type: EXPERIMENTAL
Intervention: Inhaled Magnesium sulfate (MgS04)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of MgS04 and salbutamol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 13
Study: 359108

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (mean dose 2.0 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine sulphate (10 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (average 4.6 mg per patient)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine sulphate (average 22.8 mg per patient)
Number of subjects: 50
Study: 31852492

Group type: COMPARATOR
Intervention: Mailed notification (usual care)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Mailed notification plus written educational materials (enhanced)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Mailed notification, written educational materials, plus verbal explanation by a promotora (interpersonal)
Number of subjects: 2000
Study: 27986461

Group type: EXPERIMENTAL
Intervention: Hourly titrated-dose oral misoprostol solution (20 μg hourly, increased to 40 μg and then to 60 μg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: 2-hourly static-dose oral misoprostol solution (25 μg every 2 hours)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Hourly titrated-dose oral misoprostol solution
Number of subjects: 146

Group type: COMPARATOR
Intervention: 2-hourly static-dose oral misoprostol solution
Number of subjects: 146
Study: 26356393

Group type: EXPERIMENTAL
Intervention: Divasa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 40
Study: 23315029

Group type: EXPERIMENTAL
Intervention: Olaparib 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib (all doses)
Number of subjects: 60
Study: 21075757

Group type: EXPERIMENTAL
Intervention: Skin adhesive (Group 1)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Absorbable intracutaneous suture (Group 2)
Number of subjects: 368
Study: 19261769

Group type: EXPERIMENTAL
Intervention: Zostavax
Number of subjects: 0
Study: 17721555

Group type: EXPERIMENTAL
Intervention: 10 ml bolus doses of 0.1% bupivacaine with butorphanol 2 mg (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 ml of 0.25% plain bupivacaine (Group B)
Number of subjects: 20
Study: 15534060

Group type: EXPERIMENTAL
Intervention: (90)Y-glass microspheres
Number of subjects: 27
Study: 11822630

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9706733

Group type: EXPERIMENTAL
Intervention: Topiramate (Topamax)
Number of subjects: 534
Study: 7933501

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane Anesthesia (SA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane Anesthesia (SA)
Number of subjects: 30
Study: 2904778

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms, 2 puffs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 40
Study: 30198624

Group type: EXPERIMENTAL
Intervention: Nurse managers
Number of subjects: 339

Group type: COMPARATOR
Intervention: Registered nurses
Number of subjects: 339
Study: 28120486

Group type: EXPERIMENTAL
Intervention: BI 409306 (25-, 50-, 100-, and 200-mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26573448

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hoku point ice massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual labor care
Number of subjects: 90
Study: 23734921

Group type: EXPERIMENTAL
Intervention: Cognitive and interpersonal group therapy
Number of subjects: 80
Study: 21123833

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 244

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 244
Study: 18796160

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d (300 mg BID)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 17022857

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, titrated to 0.012 mg/kg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 14620122

Group type: EXPERIMENTAL
Intervention: Polydioxanon (test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 15
Study: 11087880

Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Lidocaine alone (3 ml of 3 percent lidocaine, 91 patients)
Number of subjects: 277

Group type: COMPARATOR
Intervention: No treatment (90 patients)
Number of subjects: 277
Study: 9064551

Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unspecific psychotherapy
Number of subjects: 0
Study: 1582300

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol DP capsules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol DP capsules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 48 micrograms formoterol DP capsules
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 micrograms formoterol MDI
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 4075796

Group type: EXPERIMENTAL
Intervention: Continuous vitamin supplementation (10 mg vitamin B6 daily or twice the dose daily for 7 non-hormone days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous supplementation regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent supplementation regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive treatment
Number of subjects: 0
Study: 31760846

Group type: EXPERIMENTAL
Intervention: Topical cedar solution plus clindamycin 1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical placebo plus 1% clindamycin
Number of subjects: 80
Study: 31525542

Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant ESBL-producing Enterobacterales (n=48, 27.4% of total isolates)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: blaNDM
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: blaNDM/OXA-181
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: blaOXA-181
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: blaNDM/OXA-48
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: No carbapenase detected
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MLST sequence types
Number of subjects: 175
Study: 29381544

Group type: EXPERIMENTAL
Intervention: 1 mL of small‐particle hyaluronic acid with lidocaine (SP‐HAL) microaliquots
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham injection of sterile normal saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SP‐HAL treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cheek (normal saline)
Number of subjects: 20
Study: 26840134

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 2399
Study: 24214315

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 2
Study: 22117732

Group type: EXPERIMENTAL
Intervention: Minimally rough implants (turned)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderately rough implants (TiUnite)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of clinical parameters between turned and TiUnite implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bone loss in partial edentulous subgroup
Number of subjects: 18
Study: 19174782

Group type: EXPERIMENTAL
Intervention: Diclofenac (150 mg daily)
Number of subjects: 17289

Group type: COMPARATOR
Intervention: Etoricoxib (60 or 90 mg daily)
Number of subjects: 17289
Study: 17701770

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT), mean duration of exposure 8.3 years, 31% exposed for >=10 years
Number of subjects: 6755

Group type: COMPARATOR
Intervention: Control group (unexposed to HRT)
Number of subjects: 6755

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - route of administration
Number of subjects: 6755

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - type of HRT
Number of subjects: 6755
Study: 16103769

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Overall resistance mutations
Number of subjects: 460
Study: 11936169

Group type: EXPERIMENTAL
Intervention: Structured training for 12 weeks via laptop computer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Incidental exposure to music in daily routine
Number of subjects: 24
Study: 10530838

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unicompartmental Knee Replacement (UKR)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) with lateral release
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) without lateral release
Number of subjects: 84
Study: 8577010

Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 micrograms 5 to 7 times per week for 4 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 10
Study: 1955054

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Operative peripheral iridectomy
Number of subjects: 52
Study: 6894722

Group type: EXPERIMENTAL
Intervention: Iodoxamate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iotroxamate
Number of subjects: 100
Study: 30646403

Group type: EXPERIMENTAL
Intervention: High definition white-light colonoscopy
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Conventional white-light colonoscopy
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Virtual chromoendoscopy
Number of subjects: 1855

Group type: COMPARATOR
Intervention: High definition virtual chromoendoscopy
Number of subjects: 1855
Study: 28216083

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 400IU or 4400IU per day during pregnancy
Number of subjects: 43
Study: 27422026

Group type: EXPERIMENTAL
Intervention: Biomarker-guided recommendation on antibiotics (BAL fluid tested for IL-1β and IL-8 in addition to routine microbiology testing)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine use of antibiotics (BAL undergoes routine microbiology testing only)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Biomarker-guided recommendation on antibiotics
Number of subjects: 210
Study: 25117806

Group type: EXPERIMENTAL
Intervention: Pre-filled blister packaging labeled for daily use with reminders (MeadWestvaco Corporation's pre-filled DosePak® containing standard doses of statins)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Pre-filled blister packaging
Number of subjects: 250
Study: 21593282

Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 4% alcohol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 20% alcohol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 40% alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: MS-sNT administered with water
Number of subjects: 32
Study: 19085741

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube-D (LT-D)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laryngeal Mask (LMA)
Number of subjects: 200
Study: 17561466

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15675212

Group type: EXPERIMENTAL
Intervention: +IV group (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: -IV group (n=11)
Number of subjects: 22
Study: 12613392

Group type: EXPERIMENTAL
Intervention: Yoga asanas (Suryanamskar, Tadasan, Konasan, Padmasan, Pranayam, Paschimottansan, Ardhmatsyendrasan, Shavasan, Pavanmukthasan, Sarpasan) performed for 30‐40 minutes every day for 40 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (prescribed medication and light physical exercises like walking).
Number of subjects: 20
Study: 10350956

Group type: EXPERIMENTAL
Intervention: Providing social history information to house staff
Number of subjects: 134

Group type: COMPARATOR
Intervention: Not providing social history information to house staff
Number of subjects: 134
Study: 7651647

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 or 7.5 mg) in three monthly doses
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (GnRH agonist)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2613931

Group type: EXPERIMENTAL
Intervention: Adhesive antibiotic TA (0.1 mg, 4 applications)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 361346

Group type: EXPERIMENTAL
Intervention: Nefopam (90 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30255229

Group type: EXPERIMENTAL
Intervention: Highest quartile of S-25(OH)D levels (105.3 nmol/L)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Middle quartiles of S-25(OH)D levels (74.5 nmol/L and 85.7 nmol/L)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Lowest quartile of S-25(OH)D levels (59.3 nmol/L)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: All quartiles
Number of subjects: 387
Study: 28647010

Group type: EXPERIMENTAL
Intervention: Social Skills Group Training (SSGT)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 296
Study: 25052160

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23875181

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 63

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study: 21391759

Group type: EXPERIMENTAL
Intervention: 150 IU of rFSH and 75 IU of rLH (group B)
Number of subjects: 999

Group type: COMPARATOR
Intervention: 150 IU of rFSH (group A)
Number of subjects: 999
Study: 19646194

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 mg rosiglitazone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17674415

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg three times per day, n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 36
Study: 15730685

Group type: EXPERIMENTAL
Intervention: Dermal template overlain with thin split‐thickness autograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thin split‐thickness autograft only (Control)
Number of subjects: 20
Study: 11518688

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed meal + acarbose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate-free meal after sucrose and acarbose ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study: 9017481

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (2-cc vials)
Number of subjects: 46
Study: 8357508

Group type: EXPERIMENTAL
Intervention: Advanced Design Reach toothbrush
Number of subjects: 90

Group type: COMPARATOR
Intervention: Crest Complete toothbrush
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral‐B 40 toothbrush
Number of subjects: 90
Study: 3531313

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined omeprazole groups
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg vs Ranitidine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Follow-up after 6 months
Number of subjects: 105
Study: 29235360

Group type: EXPERIMENTAL
Intervention: PEGPH20 with gemcitabine and nab-paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27402332

Group type: EXPERIMENTAL
Intervention: Additional parenting intervention (4-6 home visits between 18 and 22 months CA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Additional parenting intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 24107382

Group type: EXPERIMENTAL
Intervention: High concern about falling (FES-I ≥ 20)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Health-related variables, functional performance tests, physical activity, quality of life
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Difficulties in instrumental activities of daily living, balance, outdoor mobility
Number of subjects: 409
Study: 22622345

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 0
Study: 20864600

Group type: EXPERIMENTAL
Intervention: SNRB+PT (Selective Nerve Root Block + Physical Therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: SNRB (Selective Nerve Root Block alone)
Number of subjects: 44
Study: 18343300

Group type: EXPERIMENTAL
Intervention: Surgical interventions (specifics not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmaceutical treatments (specifics not available)
Number of subjects: 0
Study: 15259396

Group type: EXPERIMENTAL
Intervention: fMRI during incidental encoding and recognition tasks for colored and black and white photographs
Number of subjects: 10

Group type: COMPARATOR
Intervention: fMRI during incidental encoding and recognition tasks
Number of subjects: 10
Study: 9688386

Group type: EXPERIMENTAL
Intervention: Group A: 75 IU FSH per ampoule, two ampoules on cycle day 4, one ampoule on days 6 and 8 (total four ampoules)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Group B: two ampoules on days 4, 6 and 8 (total six ampoules)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Group C: two ampoules on days 4, 6, 8 and 10 (total eight ampoules)
Number of subjects: 63